TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors (NASDAQ:TGTX)

seekingalpha.com · 2026-08-22

TG Therapeutics is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. Learn why TGTX stock is a buy.

TickrTrends take: TG Therapeutics operates in the Healthcare sector where successful drug commercialization can rapidly expand market opportunity and attract acquisition interest. TickrTrends currently derives an Undervalued verdict for TGTX, suggesting the market may not be fully pricing in the growth potential of Briumvi, particularly if buyout speculation gains momentum. Investors focused on valuation should monitor whether enthusiasm around Briumvi's commercial performance begins to narrow the gap between current market pricing and the company's intrinsic value.

Read the full story at seekingalpha.com →